Spero Therapeutics Announces Third Quarter 2023 Operating Re

Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET...

Related Keywords

Japan , Massachusetts , United States , Cambridge , Cambridgeshire , United Kingdom , Sath Shukla , Lora Grassilli , Keith Rodvold , Kevin Winthrop , Jonb Bruss , Ankit Mahadevia , Ted Jenkins , Esther Rajavelu , Satyavrat Sath Shukla , Department Of The Army , Office Of The , Intravenous Administration To Healthy Adult , Health Media Relations , Warfighter Medical Research Program Under Award No , Administration For Strategic Preparedness , Spero Therapeutics Inc , Department Of Health , Health Affairs , Development Authority , Tebipenem Hbr Research , Drug Administration , Zeno Group , Globenewswire Inc , Nasdaq , Exchange Commission , Savior Lifetec Corporation , Human Services , National Institutes Of Health , Department Of Defense , National Institute Of Allergy , Government Agency Research , Biomedical Advanced Research , Special Protocol Assessment Agreement , First Patient , First Visit , Chief Executive Officer , Upcoming Anticipated , Special Protocol Assessment , Expert Review , Investigational New Drug , Pulmonary Epithelial Lining Fluid , Alveolar Macrophages , Healthy Adult Subjects , Antimicrobial Agents , Chief Financial Officer , Chief Business , Savior Lifetec , Quarterly Report , Strategic Preparedness , Advanced Research , Assistant Secretary , Joint Warfighter Medical Research Program , Infectious Diseases , Relations Contact , Investor Relations , Health Media , Consolidated Statements , Markets ,